Loading...

Loading...

Novo Nordisk’s Amycretin Shows Promise in Early Trials
Novo Nordisk’s Amycretin Shows Promise in Early Trials
By MBN Staff - Tue, 09/17/2024 - 17:12
Novo Nordisk's amycretin shows a 13.1% weight loss in early trials with mild side effects, potentially revolutionizing obesity treatment.

Featured content

Most popular

Partnership Content

Cluster Automotriz Nuevo Leon
https://mexicobusiness.news/tag/amycretin
More Health
Weight-Loss Drug Market Heats Up With Innovations
Weight-Loss Drug Market Heats Up With Innovations
By MBN Staff - Thu, 06/20/2024 - 10:26
Global obesity rates are driving demand for safe, effective weight-loss drugs, prompting heavy pharmaceutical R&D investment.